Brussels plasma specialist acquired by Indian pharma giant
A biopharmaceutical company based in Brussels that extracts antibodies, coagulation factors and other raw materials for medicines from donor blood plasma is being acquired by a subsidiary of the Indian multinational Intas, De Tijd writes.
Prothya Biosolutions, which originated from a division of the Red Cross, also operates a Dutch factory and plasma centres in Hungary. The buyer, Accord Plasma, is a family-owned company that mainly produces generic medicines but is also active in plasma medicines.
With the acquisition of Prothya, based in Neder-Over-Hembeek, Intas hopes to gain a share of the fast-growing market for plasma-derived medicines, a sector dominated by a handful of multinationals.
Global platform
“We are delighted to expand our plasma business through the acquisition of Prothya Biosolutions,” Intas and Accord chair Binish Chudgar said in a press release.
“Combined with our fractionation capabilities in India, this positions us to create a truly global plasma platform — serving patients worldwide with critical, often under-prescribed, therapies.”
Prothya Biosolutions has had a few difficult years, mainly due to problems in the Netherlands. Last year, the group’s turnover fell by 12 per cent to 267.9 million euros. It has 1,200 employees, 350 of whom are based in Belgium.
The company was previously owned by the Dutch blood bank Sanquin. It was taken over in 2021 by a consortium of international investors led by Fortissimo Capital, an Israeli fund that made its fortune with SodaStream.
Illustration © PHOTO MATTHIEU DELATY / HANS LUCAS VIA AFP
Related news
